275 related articles for article (PubMed ID: 35354495)
21. Clinical Epigenomic Explanation of the Epidemiology of Cannabinoid Genotoxicity Manifesting as Transgenerational Teratogenesis, Cancerogenesis and Aging Acceleration.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834053
[TBL] [Abstract][Full Text] [Related]
22. Impact of converging sociocultural and substance-related trends on US autism rates: combined geospatiotemporal and causal inferential analysis.
Reece AS; Hulse GK
Eur Arch Psychiatry Clin Neurosci; 2023 Apr; 273(3):699-717. PubMed ID: 35779123
[TBL] [Abstract][Full Text] [Related]
23. Geospatiotemporal and causal inference study of cannabis and other drugs as risk factors for female breast cancer USA 2003-2017.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvac006. PubMed ID: 35386387
[TBL] [Abstract][Full Text] [Related]
24. Epidemiological overview of multidimensional chromosomal and genome toxicity of cannabis exposure in congenital anomalies and cancer development.
Reece AS; Hulse GK
Sci Rep; 2021 Jul; 11(1):13892. PubMed ID: 34230557
[TBL] [Abstract][Full Text] [Related]
25. Cannabis- and Substance-Related Carcinogenesis in Europe: A Lagged Causal Inferential Panel Regression Study.
Reece AS; Bennett K; Hulse GK
J Xenobiot; 2023 Jul; 13(3):323-385. PubMed ID: 37489337
[TBL] [Abstract][Full Text] [Related]
26. European epidemiological patterns of cannabis- and substance-related congenital cardiovascular anomalies: geospatiotemporal and causal inferential study.
Reece AS; Hulse GK
Environ Epigenet; 2022; 8(1):dvac015. PubMed ID: 35966825
[TBL] [Abstract][Full Text] [Related]
27. Patterns of Cannabis- and Substance-Related Congenital General Anomalies in Europe: A Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Pediatr Rep; 2023 Feb; 15(1):69-118. PubMed ID: 36810339
[TBL] [Abstract][Full Text] [Related]
28. European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Neurological Anomalies: Geospatiotemporal and Causal Inferential Study.
Reece AS; Hulse GK
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612763
[TBL] [Abstract][Full Text] [Related]
29. Geospatiotemporal and Causal Inferential Study of European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Orofacial Anomalies.
Reece AS; Hulse GK
J Xenobiot; 2023 Feb; 13(1):42-74. PubMed ID: 36810431
[TBL] [Abstract][Full Text] [Related]
30. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
31. Chromothripsis and epigenomics complete causality criteria for cannabis- and addiction-connected carcinogenicity, congenital toxicity and heritable genotoxicity.
Reece AS; Hulse GK
Mutat Res; 2016 Jul; 789():15-25. PubMed ID: 27208973
[TBL] [Abstract][Full Text] [Related]
32. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
33. Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends.
Reece AS; Hulse GK
Clin Pediatr (Phila); 2019 Sep; 58(10):1085-1123. PubMed ID: 31288542
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
Ligresti A; Moriello AS; Starowicz K; Matias I; Pisanti S; De Petrocellis L; Laezza C; Portella G; Bifulco M; Di Marzo V
J Pharmacol Exp Ther; 2006 Sep; 318(3):1375-87. PubMed ID: 16728591
[TBL] [Abstract][Full Text] [Related]
35. Quantitation of Δ8-THC, Δ9-THC, Cannabidiol and 10 Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS-MS.
Lin L; Amaratunga P; Reed J; Huang P; Lemberg BL; Lemberg D
J Anal Toxicol; 2022 Feb; 46(1):76-88. PubMed ID: 33270860
[TBL] [Abstract][Full Text] [Related]
36. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
37. Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.
Černe K
Arh Hig Rada Toksikol; 2020 Mar; 71(1):1-11. PubMed ID: 32597140
[TBL] [Abstract][Full Text] [Related]
38. Cannabis constituents reduce seizure behavior in chemically-induced and scn1a-mutant zebrafish.
Thornton C; Dickson KE; Carty DR; Ashpole NM; Willett KL
Epilepsy Behav; 2020 Sep; 110():107152. PubMed ID: 32585475
[TBL] [Abstract][Full Text] [Related]
39. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Niesink RJ; Rigter S; Koeter MW; Brunt TM
Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
[TBL] [Abstract][Full Text] [Related]
40. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
